A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics, and Antiviral Activity of PGDM 1400 and PGT 121 Monoclonal Antibodies in HIV-infected Adults
- ClinicalTrials.gov Identifier: NCT03205917
- Protocol Number: 2017P000232
- Principal Investigator: Boris Juelg
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required